BMC Psychiatry 2014 14:191 https://doi.org/10.1186/1471-244X-14-191
ДОПОЛНЕНИЕ
СЛУГИ ТЕСТИРОВАНИЯ НА ВИЧ
ДЕКАБРЬ 2016 г.
This report is intended to provide information regarding reporting status of the public and private hospitals, availability and utilization of hospital services, performance of the hospitals under administration of Ministry of Health, hospital deliveries and leading causes of hospitalization and mor...tality. The varieties of presentation were used to illustrate different utilization patterns according to geographical distribution and hospital types. Changes of hospital statistics over time were elicited with graphical and tabular presentation.
more
BMC Family Practice201415:165, DOI: 10.1186/1471-2296-15-165
Open Access
Int J Health Geogr. 2002; 1: 5.
Published online 2002 Dec 20. doi: 10.1186/1476-072X-1-5
PMCID: PMC149400
PMID: 12537588
Harm reduction: evidence, impacts and challenges
-10-
Module 12:
Adolescents and young adults
July 2018
Module 12: Adolescents and young adults. This module is for people who are interested in providing PrEP services to older adolescents and young adults who are at substantial risk for HIV. It provides information on: factors that influence HIV... susceptibility among young people; clinical considerations for safety and continuation on PrEP; ways to improve access and service utilization; and inclusive monitoring approaches to improve the recording and reporting of data on young people.
more
Available in different languages: English, French, Arabic, Russian
BioMed Central DOI 10.1186/s12963-016-0096-y
These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M...edicine Regulatory Harmonization (EAC MRH) Project. The group relied on their experiences and knowledge on medicines registration requirements of their individual Countries. World Health Organization (WHO) and the International Conference on Harmonization of Technical Requirements of Medicines for Human Use (ICH) and other available literature.
more
Guide to monitoring and evaluating
November 3, 2009https://doi.org/10.1371/journal.pmed.1000176
PLoS Med 6(11): e1000176. https://doi.org/10.1371/journal.pmed.1000176
HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it ...require personnel and laboratory infrastructure that are often lacking. An alternative specimen type is dried blood spots (DBS), which can be made without special laboratory processing. DBS are more easily transported than plasma because they can be shipped at ambient temperature as non-hazardous materials using regular mail or courier services.
3rd edition
more
Evaluation report
January 2014
Module 9
Strategic planning
July 2017
Module 9: Strategic planning. As WHO recommends offering PrEP to people at substantial HIV risk, this module offers public health guidance for policy-makers on how to prioritize services, in order to reach those who could benefit most from PrEP, and in wh...ich settings PrEP services could be most cost-effective.
more